═══════════════════════════════════════════════════════════════════════════
AUTHOR STATEMENTS FOR MANUSCRIPT SUBMISSION
═══════════════════════════════════════════════════════════════════════════

Title: Molecular Subtypes in Adult Acute Myeloid Leukemia Predict Venetoclax
       Response Independent of Genomic Alterations

Date: 2025-12-09

═══════════════════════════════════════════════════════════════════════════
1. AUTHOR CONTRIBUTIONS (CRediT Taxonomy)
═══════════════════════════════════════════════════════════════════════════

[Author 1 Name]:
  ☐ Conceptualization
  ☐ Data curation
  ☐ Formal analysis
  ☐ Investigation
  ☐ Methodology
  ☐ Software
  ☐ Validation
  ☐ Visualization
  ☐ Writing - original draft
  ☐ Writing - review & editing

[Author 2 Name]:
  ☐ Conceptualization
  ☐ Funding acquisition
  ☐ Investigation
  ☐ Methodology
  ☐ Project administration
  ☐ Resources
  ☐ Supervision
  ☐ Writing - review & editing

[Author 3 Name]:
  ☐ Data curation
  ☐ Formal analysis
  ☐ Software
  ☐ Validation
  ☐ Visualization

[Continue for all authors...]

NARRATIVE SUMMARY:
[Author 1] and [Author 2] conceived and designed the study. [Author 1]
performed all computational analyses, developed the gene classifier and VRS
tool, and created all figures. [Author 3] provided bioinformatics support
and validated analytical methods. [Author 4] provided clinical expertise
and interpreted results. [Author 2] supervised the project and obtained
funding. [Author 1] wrote the initial draft. All authors critically reviewed
and approved the final manuscript.

═══════════════════════════════════════════════════════════════════════════
2. COMPETING INTERESTS STATEMENT
═══════════════════════════════════════════════════════════════════════════

The authors declare no competing interests.

[OR, if conflicts exist:]

[Author Name] has received consulting fees from [Company] and research
funding from [Company], unrelated to this work. [Author Name] is a
co-inventor on a patent application related to [Topic], filed by
[Institution]. All other authors declare no competing interests.

═══════════════════════════════════════════════════════════════════════════
3. DATA AVAILABILITY STATEMENT
═══════════════════════════════════════════════════════════════════════════

PUBLICLY AVAILABLE DATA:

BeatAML cohort data:
- RNA-seq, mutation, drug response, and clinical data are available through
  the Database of Genotypes and Phenotypes (dbGaP) under accession number
  phs001657.v1.p1.
- Access requires approval through dbGaP's controlled-access mechanism.
- Study information: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001657.v1.p1

TCGA-LAML cohort data:
- RNA-seq and clinical data are available through the Genomic Data Commons
  (GDC) Data Portal.
- URL: https://portal.gdc.cancer.gov/
- Project ID: TCGA-LAML
- Data are publicly accessible without restrictions.

TARGET-AML cohort data:
- Pediatric AML data are available through the TARGET Data Matrix.
- URL: https://target-data.nci.nih.gov/
- Project: Acute Myeloid Leukemia (AML)
- Data are publicly accessible.

PROCESSED DATA AND ANALYSIS CODE:

All processed data generated in this study are available at:
- GitHub repository: [INSERT URL]
- Zenodo archive: [INSERT DOI] (persistent identifier)

The GitHub repository includes:
  • Processed gene expression matrices (batch-corrected)
  • Sample cluster assignments for all cohorts
  • 50-gene classifier model (R object)
  • VRS calculation tool
  • All analysis scripts (R and Python)
  • Figure generation code
  • Supplementary data tables

COMPUTATIONAL ENVIRONMENT:

A Docker container with the complete computational environment is available at:
- Docker Hub: [INSERT URL]
- Includes all R and Python packages with exact versions
- Enables full reproducibility of all analyses

DATA RESTRICTIONS:

Raw sequencing data for the BeatAML cohort are subject to controlled access
through dbGaP due to patient privacy protections. Researchers must obtain
dbGaP approval to access individual-level data. All other data are publicly
available without restrictions.

═══════════════════════════════════════════════════════════════════════════
4. CODE AVAILABILITY STATEMENT
═══════════════════════════════════════════════════════════════════════════

All analysis code is publicly available at:
- GitHub: [INSERT REPOSITORY URL]
- Archive: Zenodo [INSERT DOI]

The repository contains:
  • Data processing scripts (R and Python)
  • Consensus clustering analysis
  • Gene signature development (random forest)
  • Survival analysis (PH-free methods)
  • Drug response analysis
  • R² improvement calculations
  • BCL-2 pathway analysis
  • Figure generation scripts
  • Statistical analysis code

Software versions:
  • R version 4.3.0
  • Python version 3.9.7
  • Key R packages: survival (3.5-5), survminer (0.4.9), meta (6.2-1),
    ConsensusClusterPlus (1.64.0), randomForest (4.7-1.1)
  • Key Python packages: pandas (1.5.3), numpy (1.24.2), scipy (1.10.1)

The Docker container provides a fully reproducible computational environment.

═══════════════════════════════════════════════════════════════════════════
5. ETHICS STATEMENT
═══════════════════════════════════════════════════════════════════════════

PATIENT CONSENT AND INSTITUTIONAL APPROVAL:

This study used de-identified data from three previously published cohorts
(BeatAML, TCGA-LAML, TARGET-AML). All original studies obtained informed
consent from patients and institutional review board (IRB) approval at
participating centers.

The current secondary analysis was approved by [Institution Name]
Institutional Review Board ([IRB Protocol Number]) as exempt research using
publicly available de-identified data. No additional patient consent was
required.

All research was conducted in accordance with the Declaration of Helsinki
and followed the ethical guidelines of [Institution Name].

═══════════════════════════════════════════════════════════════════════════
6. FUNDING STATEMENT
═══════════════════════════════════════════════════════════════════════════

This work was supported by:
  • [Grant Name] from [Funding Agency] (Grant Number: [XXX])
  • [Fellowship Name] from [Organization] (to [Author Name])
  • [Institutional Support] from [Institution]

The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.

═══════════════════════════════════════════════════════════════════════════
7. ACKNOWLEDGMENTS
═══════════════════════════════════════════════════════════════════════════

We thank the patients and families who participated in the BeatAML,
TCGA-LAML, and TARGET-AML studies. We thank the BeatAML consortium, The
Cancer Genome Atlas Research Network, and the Therapeutically Applicable
Research to Generate Effective Treatments (TARGET) initiative for generating
and sharing data.

We thank [Name] for assistance with [specific contribution]. We thank [Name]
for critical review of the manuscript. We thank [Institution] Computational
Core for computational resources.

[Author Name] is supported by [Fellowship/Training Grant].

═══════════════════════════════════════════════════════════════════════════
8. AUTHOR INFORMATION
═══════════════════════════════════════════════════════════════════════════

CORRESPONDING AUTHOR:
  Name: [Full Name]
  Email: [email@institution.edu]
  Phone: [XXX-XXX-XXXX]
  Address: [Full institutional address]
  ORCID: [0000-0000-0000-0000]

ALL AUTHORS (in order):
  1. [Author 1 Name], [Degrees], ORCID: [XXXX-XXXX-XXXX-XXXX]
  2. [Author 2 Name], [Degrees], ORCID: [XXXX-XXXX-XXXX-XXXX]
  3. [Author 3 Name], [Degrees], ORCID: [XXXX-XXXX-XXXX-XXXX]
  [Continue for all authors...]

AFFILIATIONS:
  1. Department of [Name], [Institution], [City, State, Country]
  2. Division of [Name], [Institution], [City, State, Country]
  3. Center for [Name], [Institution], [City, State, Country]
  [Continue for all affiliations...]

═══════════════════════════════════════════════════════════════════════════
9. MANUSCRIPT STATISTICS
═══════════════════════════════════════════════════════════════════════════

Word count (main text): ~8,000 words
Abstract word count: 250 words
Number of figures: 5 (main) + 8 (supplementary)
Number of tables: 4 (main) + 9 (supplementary)
Number of references: 18
Supplementary materials: Methods document + 17 supplementary items

═══════════════════════════════════════════════════════════════════════════
10. PRIOR PRESENTATION / PREPRINT
═══════════════════════════════════════════════════════════════════════════

This work has not been previously published or submitted elsewhere.

[OR, if applicable:]

Preliminary results were presented as:
  • [Conference Name], [Location], [Date] (Abstract/Poster/Talk)
  • Title: [Presentation Title]

A preprint is available at:
  • [Preprint Server]: [DOI or URL]
  • Posted: [Date]
  • Note: This manuscript represents substantial additional analysis and
    validation beyond the preprint version.

═══════════════════════════════════════════════════════════════════════════
11. CLINICAL TRIAL REGISTRATION
═══════════════════════════════════════════════════════════════════════════

Not applicable (this is a retrospective analysis).

The prospective validation trial (CLUSTER-AML, described in Supplementary
Protocol) will be registered at ClinicalTrials.gov prior to patient enrollment.

═══════════════════════════════════════════════════════════════════════════
12. PATIENT AND PUBLIC INVOLVEMENT
═══════════════════════════════════════════════════════════════════════════

Patients and the public were not involved in the design, conduct, or
reporting of this research. Study findings will be disseminated to patient
advocacy organizations ([Leukemia & Lymphoma Society], [AML Patient
Community]) through lay language summaries.

═══════════════════════════════════════════════════════════════════════════

END OF AUTHOR STATEMENTS
Created: 2025-12-09
